Lv5
1220 积分 2024-01-29 加入
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
3天前
求助中
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
4天前
已完结
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
4天前
已完结
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
9天前
已关闭
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
10天前
已完结
EXTH-80. PBI-200: IN VIVO EFFICACY OF A NOVEL, HIGHLY CNS-PENETRANT NEXT GENERATION TRK INHIBITOR
18天前
已关闭
A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors
18天前
已关闭
2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials
18天前
已关闭
Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors
18天前
已完结
627P Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
18天前
已完结
皖公网安备34019202002308
